Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Venkataramanan R et al. | Pharmacokinetics of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721261 |
Christians U et al. | High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. | 1991 | Transplant. Proc. | pmid:1721262 |
Beysens AJ et al. | FK 506: monitoring in plasma or in whole blood? | 1991 | Transplant. Proc. | pmid:1721263 |
Grenier FC et al. | A whole blood FK 506 assay for the IMx analyzer. | 1991 | Transplant. Proc. | pmid:1721264 |
Ullman KS et al. | Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. | 1991 | Transplant. Proc. | pmid:1721294 |
Sigal NH et al. | Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? | 1991 | Transplant. Proc. | pmid:1721295 |
Bierer BE et al. | FK 506 and rapamycin: molecular probes of T-lymphocyte activation. | 1991 | Transplant. Proc. | pmid:1721296 |
Tanida I et al. | Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. | 1991 | Transplant. Proc. | pmid:1721297 |
Nakata S et al. | Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. | 1991 | Transplant. Proc. | pmid:1721325 |
Cooper MH et al. | Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. | 1991 | Transplant. Proc. | pmid:1721326 |
Didlake R and Grogan J | Effect of FK 506 on rat leukocyte chemotaxis. | 1991 | Transplant. Proc. | pmid:1721327 |
Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
Van Thiel DH et al. | Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1721357 |
Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721358 |
Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721359 |
Dew MA et al. | Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721360 |
McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
Starzl TE et al. | Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. | 1991 | Transplant. Proc. | pmid:1703351 |
Schmidt RJ et al. | Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721390 |
Tze WJ et al. | Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. | 1991 | Transplant. Proc. | pmid:1721391 |
Doi R et al. | Mechanisms by which FK 506 affects exocrine pancreas in rats. | 1991 | Transplant. Proc. | pmid:1721392 |
Rilo HL et al. | Effect of FK 506 on function of human islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1721393 |
Carroll PB et al. | Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. | 1991 | Transplant. Proc. | pmid:1721394 |
Boggs S et al. | FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. | 1991 | Transplant. Proc. | pmid:1721420 |
Cooper MH et al. | Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. | 1991 | Transplant. Proc. | pmid:1721421 |
Yoshimi F et al. | Canine total orthotopic small bowel transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721422 |
Santiago SF et al. | Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. | 1991 | Transplant. Proc. | pmid:1721423 |
Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
Sainsbury TS et al. | Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. | 1991 | Transplant. Proc. | pmid:1721453 |
Fujino Y et al. | FK 506 treatment of experimental autoimmune uveoretinitis in primates. | 1991 | Transplant. Proc. | pmid:1721454 |
Liversidge J et al. | FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. | 1991 | Transplant. Proc. | pmid:1721455 |
Mochizuki M et al. | A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. | 1991 | Transplant. Proc. | pmid:1721456 |
Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
Yoshimura R et al. | A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. | 1991 | Transplant. Proc. | pmid:1703686 |
Miyagawa S et al. | Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. | 1991 | Transplant. Proc. | pmid:1703687 |
Carroll PB et al. | Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1703688 |
Sakr MF et al. | Protective effect of FK 506 against hepatic ischemia in rats. | 1991 | Transplant. Proc. | pmid:1703689 |
Katayama Y et al. | Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1703690 |
Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |
Jamieson NV et al. | Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. | 1991 | Clin Transpl | pmid:1726459 |
Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |